REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets tough cancers in early safety trial
Disease control Recruiting nowThis is a first-in-human study to find a safe dose of a new oral drug called IACS-6274. It will be tested alone and in two different drug combinations in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the safety …
Matched conditions: REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
Blood pressure pill joins fight against tough head & neck cancers
Disease control Recruiting nowThis early-stage study is testing if a three-part treatment is safe and effective for people with head and neck cancer that has come back, spread a little, or hasn't responded to other treatments. The treatment combines a common blood pressure drug (losartan), an immunotherapy dr…
Matched conditions: REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for Tough-to-Treat head and neck cancers: can a drug duo outperform the standard?
Disease control Recruiting nowThis study is for people with advanced head and neck cancer that has returned or spread and has stopped responding to standard platinum-based chemotherapy. It aims to see if combining two immunotherapy drugs (pembrolizumab and cetuximab) helps patients live longer than using pemb…
Matched conditions: REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC